SAN RAFAEL, Calif.–(BUSINESS WIRE)–Parnell Pharmaceuticals has announced the development of an antiviral treatment to be used as a topical nasal spray as prophylaxis against COVID-19. Nomovid™ Nasal Spray will be easy to use, low-cost and can be quickly made available over-the-counter for consumers.
Nomovid is based upon a substance licensed by Parnell from New Mexico Tech University to treat drug-resistant bacteria and fungi such as MRSA and Candida auris. Since it breaks down lipids in the viral envelope, we tested it against the novel coronavirus. “An independent, outside laboratory has confirmed our findings and found it to be greater than 99.9% effective in vitro against the SARS-CoV-2 virus,” said Dr. Francis Parnell, Chairman and C.E.O. of Parnell Pharmaceuticals.
“Our product is based upon existing FDA approvals of the active ingredients for use in intravenous and inhalation formulations for other indications. Since the nose is the main route of entry into the body of SARS-CoV-2, we have prepared it in a nasal spray,” Parnell said.
Parnell has applied for funding from the U.S. government program Operation Warp Speed, and asked for an Emergency Use Authorization, which will allow the product to be manufactured and distributed while doing the necessary Phase III Clinical Trials.
Parnell Pharmaceuticals, Inc. is a closely held, private pharmaceutical company founded in 1986 and headquartered in San Rafael, California with an office in Dublin, Ireland. The company develops, manufactures, and markets prescription and OTC drug products that maintain and restore mucosal and skin integrity. The products are natural-based and patented for oral and nasal care, personal care, and anti-infective use. Parnell products are marketed and distributed in North America and Europe.
Contacts
Francis Parnell, M.D.
(415) 256-1800
www.parnellpharm.com